PMID: 2502822Feb 1, 1989Paper

Thrombolytic agents: efficacy in relation to evolution time and dose

Revista clínica española
L J García FradeJ L Navarro

Abstract

"In vitro" efficacy of urokinase (UK), streptokinase (SK) and tissue-type plasminogen activator (t-PA) was studied. Lytic action was measured by dry clot weight, 125I counts released from previously incorporated 125I-fibrinogen and fibrin fragment quantification at 1, 3 and 7 days using different doses. t-PA doses between 100 and 0.8 IU/ml were efficient. t-PA (40 IU/ml), SK (200 IU/ml) and UK (200 IU/ml) showed an equivalent activity in 1, 3 and 7 day-old clots. Fibrin fragment (D-D dimer) production was highest when t-PA and UK were used. "In vitro" lytic capacity up to 7 days after clot formation has been proved with the different fibrinolytic agents.

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.